Oncology Research and Treatment
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
Inhaltsverzeichnis
- 1
-
Editorial Board / Contents / Imprint / Guidelines for Authors| 2016
- 8
-
Pathogenesis, Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Exciting TimesHallek, Michael et al. | 2016
- 9
-
Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor MicroenvironmentFrenzel, Lukas P. / Reinhardt, H. Christian / Pallasch, Christian P. et al. | 2016
- 18
-
Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic LeukemiaLangerbeins, Petra / Groß-Ophoff-Müller, Carolin / Herling, Carmen D. et al. | 2016
- 25
-
State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic LeukemiaCramer, Paula / Hallek, Michael / Eichhorst, Barbara et al. | 2016
- 34
-
Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic LeukemiaTausch, Eugen / Mertens, Daniel / Stilgenbauer, Stephan et al. | 2016
- 41
-
Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014Weide, Rudolf / Feiten, Stefan / Friesenhahn, Vera et al. | 2016
- 45
-
Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western ChinaLiang, Rong / Wang, Zhe / Bai, Qing-Xian et al. | 2016
- 54
-
Reactive Oxygen Species Mediate TNF-⍺ Cytotoxic Effects in the Multidrug-Resistant Breast Cancer Cell Line MCF-7/MXGhandadi, Morteza / Behravan, Javad / Abnous, Khalil et al. | 2016
- 61
-
Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer PatientsShin, Seunghyeon / Pak, Kyoungjune / Park, Do Youn et al. | 2016
- 67
-
Ongoing Clinical Trials| 2016
- 69
-
A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL14)| 2016
- 73
-
Reports of Oncological Societies| 2016
- 78
-
PharmaForum| 2016
- 83
-
PharmaNews| 2016
- 90
-
Meetings and Conferences| 2016
- I
-
Optimale Mobilisierungsstrategien für den individuellen Patienten| 2016
- V
-
Abirateronacetat: 43 Monate Überleben bei frühem Beginn| 2016